A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

December 15, 2019

Study Completion Date

February 17, 2020

Conditions
Malaria, Vivax
Interventions
DRUG

Tafenoquine

Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).

DRUG

Chloroquine

Subjects may receive chloroquine according to local/national treatment guidelines.

Trial Locations (4)

100000

GSK Investigational Site, Hanoi

700000

GSK Investigational Site, Ho Chi Minh City

Unknown

GSK Investigational Site, Montería

GSK Investigational Site, Ho Chi Minh City

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT02563496 - A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria | Biotech Hunter | Biotech Hunter